BACKGROUND: Ileal involvement in Crohn's disease (CD) is associated with NOD2 mutations and granulocyte-macrophage colony stimulating factor autoantibodies (GM-CSF Ab), and GM-CSF blockade promotes ileitis in Nod2/Card15-deficient (C15KO) mice. RALDH2-expressing dendritic cells (DC) and IL-4 promote CCR9 imprinting and small bowel homing of T lymphocytes, in conjunction with CCL25 expression by ileal epithelial cells (IEC). We hypothesized that GM-CSF neutralization promotes ileal disease by modulating expression of CCL25 by IEC and CCR9 by T lymphocytes via Nod2-dependent and independent pathways. METHODS: CCL25 and CCR9 expression were determined in pediatric CD patients stratified by GM-CSF Ab. Ileitis was induced in C15KO mice via GM-CSF Ab administration followed by nonsteroidal antiinflammatory drug (NSAID) exposure, and expression of CCL25, CCR9, FOXP3, intracellular cytokines, and RALDH2 was determined in IEC and immune cell populations. RESULTS: The frequency of CCL25(+) IEC and CCR9(+) T lymphocytes was increased in CD patients with elevated GM-CSF Ab. In the murine model, GM-CSF blockade alone induced IEC CCL25 expression, and reduced the frequency of mesenteric lymph node (MLN) CD4(+) FOXP3(+) cells, while Card15 deficiency alone enhanced MLN DC RALDH2 expression. Both GM-CSF neutralization and Card15 deficiency were required for downregulation of MLN DC IL-10 expression; under these conditions NSAID exposure led to an expansion of IL-4(+) and IL-17(+) CCR9(+) lymphocytes in the ileum. CONCLUSIONS: GM-CSF prevents ileal expansion of CCR9(+) lymphocytes via Nod2-dependent and independent pathways. CCR9 blockade may be beneficial in CD patients with elevated GM-CSF Ab.
BACKGROUND: Ileal involvement in Crohn's disease (CD) is associated with NOD2 mutations and granulocyte-macrophage colony stimulating factor autoantibodies (GM-CSF Ab), and GM-CSF blockade promotes ileitis in Nod2/Card15-deficient (C15KO) mice. RALDH2-expressing dendritic cells (DC) and IL-4 promote CCR9 imprinting and small bowel homing of T lymphocytes, in conjunction with CCL25 expression by ileal epithelial cells (IEC). We hypothesized that GM-CSF neutralization promotes ileal disease by modulating expression of CCL25 by IEC and CCR9 by T lymphocytes via Nod2-dependent and independent pathways. METHODS:CCL25 and CCR9 expression were determined in pediatric CDpatients stratified by GM-CSF Ab. Ileitis was induced in C15KO mice via GM-CSF Ab administration followed by nonsteroidal antiinflammatory drug (NSAID) exposure, and expression of CCL25, CCR9, FOXP3, intracellular cytokines, and RALDH2 was determined in IEC and immune cell populations. RESULTS: The frequency of CCL25(+) IEC and CCR9(+) T lymphocytes was increased in CDpatients with elevated GM-CSF Ab. In the murine model, GM-CSF blockade alone induced IEC CCL25 expression, and reduced the frequency of mesenteric lymph node (MLN) CD4(+) FOXP3(+) cells, while Card15 deficiency alone enhanced MLN DC RALDH2 expression. Both GM-CSF neutralization and Card15 deficiency were required for downregulation of MLN DC IL-10 expression; under these conditions NSAID exposure led to an expansion of IL-4(+) and IL-17(+) CCR9(+) lymphocytes in the ileum. CONCLUSIONS:GM-CSF prevents ileal expansion of CCR9(+) lymphocytes via Nod2-dependent and independent pathways. CCR9 blockade may be beneficial in CDpatients with elevated GM-CSF Ab.
Authors: Konstantinos A Papadakis; Carol Landers; John Prehn; Elias A Kouroumalis; Sofia T Moreno; Jose-Carlos Gutierrez-Ramos; Martin R Hodge; Stephan R Targan Journal: J Immunol Date: 2003-07-01 Impact factor: 5.422
Authors: K A Papadakis; J Prehn; S T Moreno; L Cheng; E A Kouroumalis; R Deem; T Breaverman; P D Ponath; D P Andrew; P H Green; M R Hodge; S W Binder; S R Targan Journal: Gastroenterology Date: 2001-08 Impact factor: 22.682
Authors: K A Papadakis; J Prehn; V Nelson; L Cheng; S W Binder; P D Ponath; D P Andrew; S R Targan Journal: J Immunol Date: 2000-11-01 Impact factor: 5.422
Authors: J Rodrigo Mora; Maria Rosa Bono; N Manjunath; Wolfgang Weninger; Lois L Cavanagh; Mario Rosemblatt; Ulrich H Von Andrian Journal: Nature Date: 2003-07-03 Impact factor: 49.962
Authors: Marcus Svensson; Jan Marsal; Anna Ericsson; Laura Carramolino; Therese Brodén; Gabriel Márquez; William W Agace Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: Grace Gathungu; Mi-Ok Kim; John P Ferguson; Yashoda Sharma; Wei Zhang; Sok Meng E Ng; Erin Bonkowski; Kaida Ning; Lisa A Simms; Anthony R Croft; Joanne M Stempak; Nicole Walker; Ning Huang; Yang Xiao; Mark S Silverberg; Bruce Trapnell; Judy H Cho; Graham L Radford-Smith; Lee A Denson Journal: Inflamm Bowel Dis Date: 2013-07 Impact factor: 5.325
Authors: Lee A Denson; Ingrid Jurickova; Rebekah Karns; Kelly A Shaw; David J Cutler; David Okou; C Alexander Valencia; Anne Dodd; Kajari Mondal; Bruce J Aronow; Yael Haberman; Aaron Linn; Adam Price; Ramona Bezold; Kathleen Lake; Kimberly Jackson; Thomas D Walters; Anne Griffiths; Robert N Baldassano; Joshua D Noe; Jeffrey S Hyams; Wallace V Crandall; Barbara S Kirschner; Melvin B Heyman; Scott Snapper; Stephen L Guthery; Marla C Dubinsky; Neal S Leleiko; Anthony R Otley; Ramnik J Xavier; Christine Stevens; Mark J Daly; Michael E Zwick; Subra Kugathasan Journal: Inflamm Bowel Dis Date: 2019-02-21 Impact factor: 5.325
Authors: Sandra S Wright; Anna Trauernicht; Erin Bonkowski; Courtney A McCall; Elizabeth A Maier; Ramona Bezold; Kathleen Lake; Claudia Chalk; Bruce C Trapnell; Mi-Ok Kim; Subra Kugathasan; Lee A Denson Journal: J Pediatr Gastroenterol Nutr Date: 2018-05 Impact factor: 2.839
Authors: Svetlana F Khaiboullina; Sayar Abdulkhakov; Alsu Khalikova; Dilyara Safina; Ekaterina V Martynova; Yuriy Davidyuk; Felix Khuzin; Rezeda Faizullina; Vincent C Lombardi; Georgi V Cherepnev; Albert A Rizvanov Journal: Front Microbiol Date: 2016-12-15 Impact factor: 5.640